BLISS index using WOMAC index detects between-group differences at low-intensity symptom states in osteoarthritis

Journal of Clinical Epidemiology

Volumn 63, Issue 5, 2010, Pages 566-574

  Bellamy, Nicholas ^a   Bell, Mary J ^b   Goldsmith, Charlie H ^c   Lee, Shelley ^d   Maschio, Michael ^d   Raynauld, Jean Pierre ^e   Torrance, George W ^c,d   Tugwell, Peter ^f,g  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d i3 Global   (Canada)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

^g UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Effectiveness; Hylan G F 20; Osteoarthritis; Randomized controlled trial; State attainment; WOMAC index

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ARTICLE; BLISS INDEX; CONTROLLED STUDY; HEALTH STATUS; HUMAN; JOINT STIFFNESS; KNEE FUNCTION; KNEE OSTEOARTHRITIS; KNEE PAIN; MAJOR CLINICAL STUDY; MENTAL CAPACITY; PAIN ASSESSMENT; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; TREATMENT RESPONSE; WOMAC INDEX;

AGED; BIOCOMPATIBLE MATERIALS; FEMALE; HUMANS; HYALURONIC ACID; MALE; MIDDLE AGED; OSTEOARTHRITIS, KNEE; PAIN MEASUREMENT; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77949658685     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2009.07.011     Document Type: Article

References (21)

1. Bellamy N., Wilson C., and for the REFLECT Study Group. International estimation of Minimum Clinically Important Improvement (MCII75): the Reflect Study. Intern Med J 37 Suppl 2 (2007) A36
2. Bellamy N., Wilson C., and for the REFLECT Study Group. International estimation of Patient Acceptable Symptom Severity (PASS75): the Reflect Study. Intern Med J 37 Suppl 2 (2007) A36
3. Pham T., van der Heijde D., Altman R.D., Anderson J.J., Bellamy N., Hochberg M., et al. OMERACT-OARSI initiative: osteoarthritis research society international set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 12 (2004) 389-399
4. Tubach F., Ravaud P., Baron G., Falissard B., Logeart I., Bellamy N., et al. Evaluation of clinically relevant changes in patient-reported outcomes in knee and hip osteoarthritis: the minimal clinically important improvement. Ann Rheum Dis 64 1 (2005) 29-33
5. Ehrich E.W., Davies G.M., Watson D.J., Bolognese J.A., Seidenberg B.C., and Bellamy N. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis. J Rheumatol 27 (2000) 2635-2641
6. Bellamy N., Bell M., Goldsmith C.H., Pericak D., Walker V., Raynauld J.-P., et al. Evaluation of WOMAC 20, 50, 70 response criteria in patients treated with hylan G-F 20 for knee osteoarthritis. Ann Rheum Dis 64 (2005) 881-885
7. Tubach F., Baron G., Ravaud P., Fallissard B., Logeart I., Bombardier C., et al. Evaluation of clinically relevant changes and states in symptomatic variables in osteoarthritis. Arthritis Rheum 48 Suppl (2003) S292
8. Tubach F., Ravaud P., Baron G., Falissard B., Logeart I., Bellamy N., et al. Evaluation of clinically relevant states in patient-reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis 64 1 (2005) 34-37
9. Bellamy N., Bell M.J., Pericak D., Goldsmith C.H., Torrance G.W., Raynauld J.-P., et al. BLISS index for analysing knee osteoarthritis trials data. J Clin Epidemiol 60 2 (2007) 124-132
10. Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., and Stitt L. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 15 (1988) 1833-1840
11. Bellamy N., Krupa D., Markind J.E., Reicin A.S., and Malmstrom K. Prevalence of patients with low intensity pain symptom severity states during treatment with rofecoxib and ibuprofen for osteoarthritis. OARSI Congress 2004. Osteoarthritis Cartilage 12 Suppl B (2004) S69
12. Bellamy N., Campbell J., Haraoui B., Gerecz-Simon E., Buchbinder R., Hobby K., et al. Clinimetric properties of the AUSCAN osteoarthritis hand index: an evaluation of reliability, validity and responsiveness. Osteoarthritis Cartilage 10 (2002) 863-869
13. Kvien T.K., Zhang Y.Z., Nicols M., Dougados M., Podrebarac T.A., and Bellamy N. Response and state-attainment criteria in hand OA: analyses from a placebo-controlled clinical trial of CRX-102, a novel synergistic combination therapy. Ann Rheum Dis 66 Suppl II (2007) 501
14. Raynauld J.P., Torrance G.W., Band P.A., Goldsmith C.H., Tugwell P., Walker V., et al. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (part 1 of 2): clinical results. Osteoarthritis Cartilage 10 (2002) 506-517
15. Hochberg M.C., Altman R.D., Brandt K.D., Clark B.M., Dieppe P.A., Griffin M.R., et al. Guidelines for the medical management of osteoarthritis, part II. Osteoarthritis of the knee. Arthritis Rheum 38 (1995) 1541-1546
16. Torrance G., Raynauld J.P., Walker V., Goldsmith C.H., Bellamy N., Band P., et al. A prospective randomized health outcomes trial evaluating the incorporation of hylan GF-20 into the treatment paradigm for patients with knee osteoarthritis (part 2 of 2): economic results. Osteoarthritis Cartilage 10 (2002) 518-527
17. Scale D., Wobig M., and Wolpert W. Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study. Curr Ther Res 55 (1994) 220-232
18. Wobig M., Bach G., Beks P., Dickhut A., Runzheimer J., Schwieger G., et al. The role of elastoviscosity in the efficacy of viscosupplementation for osteoarthritis of the knee: a comparison of hylan G-F 20 and a lower-molecular-weight hyaluronan. Clin Ther 21 (1999) 1549-1562
19. Little R.J.A., and Rubin D.B. Statistical analysis with missing data. 2nd ed (2002), John Wiley & Sons, Inc., Hoboken, NJ
20. Bellamy N., Wilson C., and Hendrikz J.K. Community-based normative values for disability derived from WOMAC and AUSCAN NRS 3.1 indices. Ann Rheum Dis 66 Suppl II (2007) 491
21. Bellamy N., Wilson C., and Hendrikz J. Community-based normative values for pain, stiffness and disability derived from the WOMAC NRS 3.1 index. EULAR 2008. Ann Rheum Dis 67 Suppl II (2008) 228